Order results by:
| Issue | Title | |
| Vol 8, No 2 (2015) | PHARMACOECONOMIC STUDIES TREATMENT OF PATIENTS WITH INJURIES IN THE DEPARTMENT OF ANESTHESIOLOGY AND RESUSCITATION WITH METHODS ANALYSIS THE COST OF ILLNESS | Abstract similar documents |
| Anton Alexandrovich Kasatkin | ||
| "... of treating patients with injury severity index 39 points (ISS) exceeded the cost of treating patients ..." | ||
| Vol 12, No 3 (2019) | Pharmacoepidemiological analysis of antimicrobial therapy for burn injury in the hospital settings | Abstract similar documents |
| O. V. Zhukova, E. S. Nekaeva, E. S. Khoroshavina, E. A. Kozlova, Yu. A. Dudukina, I. Yu. Arefyev | ||
| "... Aim: to conduct a pharmacoepidemiological analysis of antimicrobial therapy of burn injury ..." | ||
| Vol 7, No 1 (2014) | PATIENTS WITH NEUROLOGICAL DISEASES: RATIONALE FOR PHARMACOECONOMIC EVALUATION OF COST OPTIMIZATION FOR MANAGEMENT WITH NEURON-SPECIFIC PROTEINS ASSESSMENT AS MARKERS OF INCREASED BLOOD-BRAIN-BARRIER PERMEABILITY | Abstract similar documents |
| D. V. Blinov | ||
| "... to predict severity and outcome of epilepsy, stroke, traumatic brain injury (TBI) and other neurological ..." | ||
| Vol 17, No 1 (2024) | Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients | Abstract similar documents |
| О. I. Ivakhnenko, V. V. Ryazhenov, N. A. Falaleeva | ||
| "... direct healthcare costs and incremental cost-effectiveness ratios (ICERs) per 1 life year gained were ..." | ||
| Vol 17, No 3 (2024) | Economic analysis of implementing Systemic Coronary Risk Estimation (SCORE2) scale and long-term consequences | Abstract similar documents |
| E. O. Kurilovich, A. V. Nikitina, I. V. Sorokovikov | ||
| "... analysis of long-term consequences involved calculating the cost of pharmacotherapy and the costs ..." | ||
| Vol 7, No 1 (2014) | ABC END VEN ANALYSYS OF COSTS FOR MEDICINE SAND MEDICAL TREATMENT COSTS PATIENT | Abstract similar documents |
| M. A. Shapovalova, L. R. Koretskaya | ||
| "... of pharmacotherapy and medical services in the department of neurology. An assessment of the costs of hospitalization ..." | ||
| Vol 15, No 1 (2022) | Pharmacoeconomic analysis of using Monofer in patients with iron deficiency anemia as part of the provision of medical care under the state guarantees program in the health care system of the Russian Federation | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, V. G. Serpik, O. A. Gromova, I. Yu. Torshin | ||
| "... , costs and costeffectiveness. Comparison of preparations of oligoisomaltose iron [III] (Monofer ..." | ||
| Vol 7, No 3 (2014) | PROBLEMS OF OUTCOMES CHOICE FOR THE ASSESSMENT OF REHABILITATION PROGRAMS EFFICIENCY IN PATIENTS AFTER STROKE AND CRANIOCEREBRAL INJURY | Abstract similar documents |
| V. S. Dombrovskiy, V. V. Omelyanovskiy | ||
| "... as evaluation criteria for rehabilitation programs efficiency in patients after stroke, craniocerebral injury ..." | ||
| Vol 10, No 2 (2017) | COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS | Abstract similar documents |
| M. B. Kubaeva, Y. Sh. Guchshina | ||
| "... The aim of our study was to conduct a pharmacoeconomic and cost analysis of the therapeutic use ..." | ||
| Vol 11, No 4 (2018) | Costs of pharmacotherapy in pediatric patients with community-acquired pneumonia: mathematical and statistical analysis | Abstract similar documents |
| I. A. Narkevich, O. D. Nemyatyh, D. D. Siukaeva, I. V. Pavlushkov, D. O. Ivanov, Ya. V. Panyutina | ||
| "... for the evaluation of pharmacotherapy costs in pediatric inpatients diagnosed with community-acquired pneumonia ..." | ||
| Vol 5, No 2 (2012) | THE ANALYSIS OF COST OF ILLNESS OF PREGNANT WOMEN WITH SYPHILIS | Abstract similar documents |
| A. I. Ovod, M. D. Mukovnina | ||
| "... категории пациентов. ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis | Abstract similar documents |
| R. I. Yagudina, M. M. Murashko | ||
| "... and Sterofundin drugs were compared during the analysis. A cost analysis, cost-effectiveness analysis, budget ..." | ||
| Vol 12, No 1 (2019) | Individual cost accounting in the management of medical organizations | Abstract similar documents |
| I. A. Zheleznyakova, L. A. Kovaleva, T. A. Khelisupali | ||
| "... In the modern economic conditions, the rational planning of costs and the complex process ..." | ||
| Vol 5, No 1 (2012) | COST OF ILLNESS ANALYSIS: TYPES, METHODOLOGY, RUSSIAN SPECIFICS | Abstract similar documents |
| R. I. Yagudina, I. Yu. Zinchuk, M. M. Litvinenko | ||
| "... Cost of illness is one of the basic methods of pharmacoeconomical estimation and in substance ..." | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic analysis of the application of strong opioids for the treatment of chronic pain syndrome in patients with pancreatic cancer | Abstract similar documents |
| O. P. Bobrova, S. K. Zyryanov, N. A. Shnayder, M. M. Petrova | ||
| "... on the analysis of its cost and effectiveness in patients with chronic pain syndrome in pancreatic cancer ..." | ||
| Vol 12, No 3 (2019) | Comorbidity in elderly patients with atrial fibrillation affects the “cost of illness” | Abstract similar documents |
| S. V. Malchikova , N. S. Maksimchuk-Kolobova, M. V. Kazakovtseva | ||
| "... Objective: to analyze whether comorbidity affects the cost of treatment and medical services ..." | ||
| Vol 16, No 1 (2023) | Modern biomarkers of acute kidney injury | Abstract similar documents |
| D. I. Korabelnikov, M. O. Magomedaliev | ||
| "... The results of published studies of modern biomarkers used in the diagnosis of acute kidney injury ..." | ||
| Vol 8, No 2 (2015) | REVIEW OF THE INTERNATIONAL PRACTICE OF COST-SHARING MECHANISM IN NATIONAL HEALTH CARE SYSTEMS | Abstract similar documents |
| Natalia Nikolayevna Sisigina, Vitalii Vladimirovich Omel'yanovskii, Nikolay Alexandrovich Avxentyev | ||
| "... The article gives a review of international experience of using of cost-sharing mechanism ..." | ||
| Vol 9, No 1 (2016) | COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA | Abstract similar documents |
| G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy | ||
| "... Objective: to perform cost-effectiveness analysis of brentuximab vedotin (BV) in patients ..." | ||
| Vol 9, No 4 (2016) | COST MINIMIZATION SHALL NOT KILL PEOPLE FINAL RELEASE OF VII RUSSIAN CONGRESS OF PATIENTS | Abstract similar documents |
| Editorial article | ||
| Vol 17, No 3 (2024) | Assessment of the impact of procurement centralization on the drug provision for patients within the High-Cost Nosology Program in the Russian Federation | Abstract similar documents |
| V. V. Omelyanovskiy, V. A. Ryagina, A. G. Kharitonova, K. I. Matrenin, A. A. Kingshott, O. V. Ashikhmina, M. V. Zhirov | ||
| "... funds within High-Cost Nosology (HCN) Program. Objective: to assess the impact of drug procurement ..." | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC EVALUATION OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON DIALYSIS WITH CINACALCET | Abstract similar documents |
| R. I. Yagudina, V. G. Serpik | ||
| "... out by mean of «cost-efficacy» analysis, as the main performance indicator has been selected ..." | ||
| Vol 12, No 4 (2019) | Optimization of drug supply for patients with malignant neoplasms in a region of the Russian Federation | Abstract similar documents |
| A. V. Nikitina, F. V. Gorkavenko, Y. S. Saybel, M. V. Avxentyeva, M. S. Sura, D. V. Fedyaev | ||
| "... The aim was to assess the possibility of optimizing the costs of drugs for cancer patients ..." | ||
| Vol 14, No 3 (2021) | Health economic evaluation of risdiplam in patients with spinal muscular atrophy | Abstract similar documents |
| А. S. Kolbin, А. А. Kurylev, Yu. Е. Balykina, М. А. Proskurin, S. А. Mishinova | ||
| "... Russian regulation. Cost-minimization analysis was used. We accounted for direct medical costs ..." | ||
| Vol 17, No 2 (2024) | Cystatin C: diagnostic and prognostic value in acute kidney injury | Abstract similar documents |
| D. I. Korabelnikov, M. O. Magomedaliev | ||
| "... Acute kidney injury (AKI) is a life-threatening condition that occupies one of the leading places ..." | ||
| Vol 12, No 4 (2019) | Clinical and economic analysis of drug costs in a general hospital in 2014-2018 | Abstract similar documents |
| A. T. Burbello, A. S. Fedorenko, E. L. Latariya, M. V. Pokladova, K. A. Zagorodnikova | ||
| "... and costs of the purchased drugs as well as their current consumption by various clinical departments ..." | ||
| Vol 5, No 2 (2012) | COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS | Abstract similar documents |
| A. V. Rudakova | ||
| "... парикальцитол обеспечивает снижение протеинурии у пациентов с хронической почечной недостаточностью (ХБП) и ..." | ||
| Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
| "... ) was used as the main criterion of effectiveness. Direct medical costs of drug therapy, and the costs ..." | ||
| Vol 8, No 2 (2015) | CLINICAL EFFICIENCY AND THE PHARMACOECONOMIC ANALYSIS OF ALLERGEN IMMUNOTHERAPY AT PATIENTS WITH MILD AND MODERATE ALLERGIC BRONCHIAL ASTHMA | Abstract similar documents |
| Elena Albertovna Sobko, Natalya Vladimirovna Gordeeva, Angelina Yurievna Kraposhina, Irina Anatolyevna Soloveva, Svetlana Vladimirovna Chubarova, Olga Petrovna Ishenko, Irina Vladimirovna Demko, Maria Michailovna Loktionova | ||
| "... . For the pharmacoeconomic analysis we used the cost-effectiveness ratio. Results. Our analysis showed that the scheme ..." | ||
| Vol 13, No 4 (2020) | Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm | Abstract similar documents |
| M. Yu. Frolov, A. S. Salasyuk, V. A. Rogov | ||
| "... using the cost of illness analysis in a model developed in Microsoft Excel 2016 (Microsoft, USA ..." | ||
| Vol 16, No 4 (2023) | Analysis of the clinical and economic effectiveness of using benralizumab in comparison with standard therapy in patients with severe bronchial asthma | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, S. N. Avdeev, I. N. Barykina, V. O. Lutova, E. A. Popova | ||
| "... with an eosinophilic phenotype by means of a modeling method. Cost calculations were performed in a mathematical model ..." | ||
| Vol 9, No 1 (2016) | COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN | Abstract similar documents |
| V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva | ||
| "... according to standard pharmacoeconomic methods: cost-utility analysis (CUA), budget impact analysis (BIA ..." | ||
| Vol 13, No 4 (2020) | The social-economic burden of spinal muscular atrophy in Russia | Abstract similar documents |
| A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina | ||
| "... (medical, social etc.) throughout their life and the cost of the care has never been calculated in Russia ..." | ||
| Vol 12, No 4 (2019) | Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis | Abstract similar documents |
| I. V. Sarvilina, A. N. Galustyan, A. K. Hadzhidis, I. S. Sardaryan, N. V. Lavrov, O. A. Gromova, Yu. S. Prokofieva | ||
| "... & Lawrence classification. We calculated the cost-effectiveness from the direct costs and treatment ..." | ||
| Vol 17, No 2 (2024) | Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy | Abstract similar documents |
| S. K. Zyryanov, I. N. Dyakov | ||
| "... in terms of overall survival and progression-free survival. Therefore, a cost minimization analysis method ..." | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER | Abstract similar documents |
| A. U. Kulikov | ||
| "... . По полученным результатам, применение эрлотиниба в качестве второй линии терапии пациентов с ..." | ||
| Vol 13, No 2 (2020) | Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation | Abstract similar documents |
| S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
| "... was used for the estimation of direct medical costs associated with different medications. Costminimization ..." | ||
| Vol 9, No 2 (2016) | PHARMACOECONOMIC ANALYSIS OF THE THERAPY OF СHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS IN HOSPITAL CONDITIONS | Abstract similar documents |
| E. E. Vidyakina, S. V. Malchikova | ||
| "... records of the patient, the analysis of cost of illness, ABC VEN — analysis. Results. The results of АВС ..." | ||
| Vol 12, No 1 (2019) | Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan | Abstract similar documents |
| T. P. Bezdenezhnykh, D. V. Fedyaev, G. R. Khachatryan, G. G. Arutyunov, K. V. Gerasimova | ||
| "... costs. The present study aims to assess the economic consequences of the proposed IBD healthcare ..." | ||
| Vol 16, No 1 (2023) | Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program | Abstract similar documents |
| T. O. Bessonova, P. A. Mukhortova, R. A. Teryan, A. D. Bagdasarov, N. Z. Musina | ||
| "... . The incremental cost-effectiveness ratio (ICER) for QALY in the baseline scenario was 3,598,156 rubles, the ICER ..." | ||
| Vol 5, No 3 (2012) | COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES | Abstract similar documents |
| M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova | ||
| "... , myorelaxants, physical therapy). Measured direct costs at 1-year follow-up. Quality of life was measured ..." | ||
| Vol 6, No 2 (2013) | COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov | ||
| "... performed cost-effectiveness analysis on the basis of two tyrosine kinase inhibitors in Russian Federation ..." | ||
| Vol 10, No 1 (2017) | EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... impact and the “cost-effectiveness” parameters were analyzed using the MS Excel-model based on a 3-year ..." | ||
| Vol 16, No 3 (2023) | Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study | Abstract similar documents |
| A. S. Kolbin, Yu. M. Gomon, M. A. Proskurin, Yu. E. Balykina | ||
| "... cancer (NSCLC). Materials and methods. The calculations included the direct costs of the healthcare ..." | ||
| Vol 9, No 2 (2016) | METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY | Abstract similar documents |
| N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov | ||
| "... of this study is to compare costs associated with these options in Russia. Materials and methods. We calculated ..." | ||
| Vol 18, No 1 (2025) | Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova, D. V. Kurkin | ||
| "... for discussion. Despite the higher cost of lanreotide compared to octreotide, the former may have an advantage ..." | ||
| Vol 8, No 2 (2015) | REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS | Abstract similar documents |
| Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev | ||
| "... need a specific approach due to high costs of the drugs and limited sample size. Cost-utility analysis ..." | ||
| Vol 18, No 2 (2025) | Clinical and economic evaluation of antibacterial therapy for nosocomial pneumonia on the example of a multidisciplinary hospital in Moscow | Abstract similar documents |
| D. D. Ivanova, I. N. Sychev, N. B. Lazareva | ||
| "... pathogens were selected for analysis. Direct medical costs and cost-effectiveness coefficients were ..." | ||
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation | Abstract similar documents |
| S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev | ||
| "... . The cost-effectiveness ratios for omalizumab, mepolizumab and reslizumab were calculated and compared ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation | Abstract similar documents |
| A. Yu. Kulikov, L. A. Komarov | ||
| "... of approaches to treatment policy of this group of patients. We performed cost-effectiveness analysis ..." | ||
| 1 - 50 of 329 Items | 1 2 3 4 5 6 7 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
